A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies.
Authors: Jacob Randolph Garcia
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.tps2681
Source:
Full article
Abstract
TPS2681